Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0748
Source ID: NCT00791830
Associated Drug: Irbesartan
Title: Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan
Acronym: SAFIR
Status: COMPLETED
Study Results: NO
Results:
Conditions: Kidney Failure, Chronic
Interventions: DRUG: Irbesartan|DRUG: Placebo matching irbesartan 150 mg
Outcome Measures: Primary: Decrease in loss of residual kidney function., 3, 6, 9 and 12 months | Secondary: Cardio-vascular outcome assessed by applanation tonometry, echocardiography, Transonic measurements of cardiac output and markers in blood., 1 year|Progression to anuria, 3, 6, 9 and 12 months|Quality of life assessed by a questionnaire: Kidney Disease Quality Of Life - Short Form (KDQOL-SF), 1 year
Sponsor/Collaborators: Sponsor: University of Aarhus
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 82
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION
Start Date: 2009-04
Completion Date: 2013-01
Results First Posted:
Last Update Posted: 2013-01-08
Locations: Department of Nephrology, Aarhus University, Aalborg, Aalborg, 9000, Denmark|Department of Nephrology, Aarhus University Hospital, Skejby, Aarhus N, 8200, Denmark|Department of Medicine, Fredericia Hospital, Fredericia, 7000, Denmark|Haemodialysis unit, Horsens Hospital, Horsens, 8700, Denmark|Hemodialysis Unit, Randers Hospital, Randers, 8600, Denmark|Department of Medicine M, Viborg Hospital, Viborg, 8800, Denmark
URL: https://clinicaltrials.gov/show/NCT00791830

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D309 Irbesartan small molecule DB01029 Details